Physician profile

Mark Leo Billy

Oral & Maxillofacial Surgery · Youngstown, OH

NPI 1538143508

$826.89

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Education$200.00
Food and Beverage$160.67

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Zimvie INC. $337.78 2022-2024
Zimmer Biomet Holdings, INC. $299.08 2019-2021
Dentsply Sirona INC $137.11 2023-2024 Astra Tech Implant System
Ace Surgical Supply Co., INC. $15.77 2019-2021
Metrex Research, LLC $13.93 2021
Nobel Biocare USA $13.60 2019
Salvin Dental Specialties, INC. $9.62 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Mark Leo Billy

$826.89

in general payments reported 2019-2025

Years
2019-2024
Top company
Zimvie INC.

https://glasscript.com/doctor/24419/mark-leo-billy

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.